Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A ESTRADA

Showing results (541-550 of 545) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 545 results.
Science Translational Medicine|June 8, 2022
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's diseaseDanna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry, et al.
Journal of Medicinal Chemistry|September 19, 2012
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Xingrong Liu, Charles Baker-Glenn, et al.
Nature Communications|August 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialBrittany N Flores, Seungyoon B Yu, Isaac V Cohen, et al.
Science Translational Medicine|August 14, 2024
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrierScarlett J Barker, Mai B Thayer, Chaeyoung Kim, et al.
Allergy|June 11, 2017
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)J Bousquet, I Agache, M R Aliberti, et al.
Pageof 55

Showing results (541-550 of 545) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 545 results.
Science Translational Medicine|June 8, 2022
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's diseaseDanna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry, et al.
Journal of Medicinal Chemistry|September 19, 2012
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Xingrong Liu, Charles Baker-Glenn, et al.
Nature Communications|August 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialBrittany N Flores, Seungyoon B Yu, Isaac V Cohen, et al.
Science Translational Medicine|August 14, 2024
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrierScarlett J Barker, Mai B Thayer, Chaeyoung Kim, et al.
Allergy|June 11, 2017
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)J Bousquet, I Agache, M R Aliberti, et al.
Pageof 55